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ABSTRACT
Maintaining thiol homeostasis is an imperative for cancer cell survival in 
the nutrient-deprived microenvironment of solid tumors. Despite this metabolic 
vulnerability, a selective approach has yet to be developed to disrupt thiol homeostasis 
in solid tumors for therapeutic purposes. In this study, we report the identification 
of 2-mercaptopropionyl glycine disulfide (TTL-315) as a novel antimetabolite that 
blocks cell survival in a manner conditional on glucose deprivation. In the presence 
of glucose, TTL-315 lacks cytotoxic effects in normal cells where it is detoxified 
by reduction to 2-mercaptopropionyl glycine, a compound with known clinical 
pharmacologic and safety profiles. In several rodent models of aggressive breast, 
lung and skin cancers, TTL-315 blocked tumor growth and cooperated with the DNA 
damaging drug cisplatin to trigger tumor regression. Our results offer preclinical proof 
of concept for TTL-315 as a novel antimetabolite to help selectively eradicate solid 
tumors by exploiting the glucose-deprived conditions of the tumor microenvironment.
INTRODUCTION
Therapeutic strategies to attack common 
metabolic aberrations in cancer, including the use of 
antimetabolites, offer appeal because of their potentially 
broad applications in the treatment of patients with cancer. 
It is widely appreciated that glycolysis is activated in 
most solid tumors, but it is less known that the same is 
true for the oxidative pentose phosphate cycle (OPPC), a 
metabolic branch in the glycolysis pathway downstream 
of hexokinase. OPPC is responsible for generating 
much of the NADPH for which cancer cells require to 
maintain reduced glutathione at levels sufficient for thiol 
homeostasis and cell survival [1-5]. Solid tumors the 
requirement of solid tumors for thiol homeostasis is greater 
than normal tissues for at least two reasons. First, there is a 
heavier reliance on cell survival mechanisms in the highly 
oxidized nutrient-deprived microenvironment of a solid 
tumor. Glucose depletion occurs commonly in regions 
of bulky tumors, owing to high glucose metabolism 
combined with poor perfusion due to a disorganized 
blood vasculature. Indeed, cancer cells in the solid tumor 
microenvironment evolve responses to survive the stresses 
of glucose deprivation which overlaps with hypoxic 
regions of the tumor to significant extent [6-8]. Glucose 
deprivation places a great strain on thiol homeostasis in 
all cells because of the reliance of the OPPC pathway 
on glucose to produce NADPH, a critical factor in thiol 
homeostasis. Second, cancer cells rely heavily on DNA 
repair functions regulated by thiol redox, such as Ku or 
DNA-PK, which are involved in double strand break 
repair [4, 5, 9]. Overall, the acute need of cancer cells for 
glucose/NADPH-dependent thiol homeostasis in the solid 
tumor microenvironment highlights a general selective 
metabolic weakness that can be exploited for therapeutic 
ends. 
Recently, new evidence of the vital connection 
between NADPH production, thiol homeostasis and 
cancer cell survival under glucose-deprived conditions 
was illustrated in cell biochemistry studies with the 
compound hydroxylethyldisulfide (HEDS) [10], a 
substrate of the glutathione-dependent enzyme thioredoxin 
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reductase [11]. Under normal glucose conditions, HEDS is 
reduced to ß-mercaptoethanol (ß-ME) without toxic effect, 
but under conditions of glucose deprivation, HEDS adds 
a stress to thiol homeostasis that was sufficient to trigger 
p53-independent cell death [10]. Earlier studies of HEDS 
confirm its relationship with OPPC and thiol homeostasis 
as a probe of OPPC-dependent thiol oxidative stress and 
Ku-dependent DNA double strand break repair [3-5, 12], 
but only recently did it become apparent that HEDS is 
cytotoxic to cancer cells when glucose is deprived [10]. 
The need for thiol homeostasis to support DNA 
repair functions increases interest in dithiol compounds 
that might leverage the efficacy of DNA damaging 
therapies including chemotherapy and radiotherapy. 
Where the interface between thiol homeostasis and 
metabolism has been investigated in cancer it has mainly 
been in the context of hypoxia rather than nutrient 
deprivation. Moreover, strategies to develop selective 
cancer therapies in this area remain inchoate. Cancer cells 
located in hypoxic, glucose-deprived regions are well 
known for their recalcitrance to therapy, comprising a 
wellspring for stem-like, drug-resistant and pro-metastatic 
cell populations most often responsible for the demise 
of cancer patients. Thus, compounds that can sensitize 
glucose-deprived cancer cells to destruction may offer 
useful alternatives, alone or as adjuvants for radiotherapy 
or chemotherapy. In this study, we further develop this 
concept by offering evidence of the antitumor properties 
of a novel disulfide compound, TTL-315, which is more 
potent than similar disulfides studied previously and 
suited to consider for translation into the clinical oncology 
setting for patient treatment. 
RESULTS
TTL-315 is a cytotoxin conditional on glucose 
deprivation
Glucose is a critical nutrient for detoxification of 
the disulfide compound HEDS which under glucose-
deprived conditions in vitro triggers cancer cell death 
[10]. Based on this unique activity, in vivo tests of HEDS 
were explored but this direction was judged impractical 
due to safety concerns from systemic toxicity of the HEDS 
bioreductant ß-ME. In considering other structurally 
related disulfides with less toxic bioreductive products, 
we explored the novel compound 2-mercaptopropionyl 
glycine disulfide (TTL-315), a dimer of the approved 
clinical drug 2-mercaptopropionyl glycine, tiopronin 
(also known as thiola), as a potentially safe candidate for 
analysis (Figure 1). 
Following upon studies of HEDS response in colon 
cancer cells [10], we explored dose responses to TTL-
315 in normal and oncogene-transformed variants of the 
established rat intestinal cell line RIE and in rat MATB-
III cells, which are derived from an aggressive mammary 
carcinoma (Figure 2). The transformed character of the 
RIE/neuT cells were confirmed by their capability for 
anchorage-independent growth in soft agar culture (Suppl. 
Figure 1), as compared to the non-transformed RIE/neo 
cells and transformed RIE/Kras cells which have been 
described previously [13]. For experiments investigating 
TTL-315, equal numbers of cells were seeded into normal 
growth media and then fed the next day with growth 
media that included or lacked glucose. Four hours later, 
TTL-315 or vehicle only was added to the cultures and 
cells were incubated 24 hr before being subjected to a 
viability assay that monitors thiol homeostasis [14]. The 
results presented in Figure 2 show that TTL-315 reduced 
cell viability unless detoxified by disulfide bioreduction, 
a condition requiring glucose in the culture media. In the 
presence of glucose, addition of TTL-315 caused cell 
growth arrest, whereas in its absence the compound was 
cytotoxic. Non-transformed RIE/neo cells did not display 
toxicity to TTL-315 in the presence of glucose, which was 
also the case to some lesser extent in the transformed RIE/
Kras and RIE/neuT cells and the cancer-derived MATB-
III cells. However, in the absence of glucose TTL-315 
was universally cytotoxic, with the transformed cells 
exhibiting relatively greater sensitivity. The cytotoxic 
properties of TTL-315 in glucose-deprived cell cultures 
was confirmed in other standard cell viability assays (data 
not shown), arguing against a misleading interpretation 
of the primary assay. Although further work was needed 
Figure 1: Chemical structure of TTL-315 and its bioreductive relationship with 2-mercaptopropionyl glycine 
(tiopronin). TTL-315 is the oxidized disulfide of the generic clinical drug tiopronin (2-mercaptopropionyl glycine). Under normative 
tissue reducing conditions where glucose is available, tiopronin is the bioreductant of TTL-315.
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to fully understand the detoxification reaction, the results 
suggested that like HEDS itself [10] a latent cytotoxic 
property of TTL-315 was unmasked in settings of glucose 
deprivation. 
TTL-315 blocks the growth of tumors and induces 
tumor regression when combined with cisplatin
To begin to assess the conditional cytotoxic effects 
of TTL-315 in the setting of solid tumors, we embarked on 
a series of experiments in various established preclinical 
rodent models of breast, lung and skin cancer. MATB-
III is an aggressive rat mammary carcinoma the rapid 
growth of which produces a highly nutrient-deprived 
tumor microenvironment. In an initial test of the ability 
of TTL-315 to block tumor growth, we treated MATB-
III tumor-bearing mice as tumors became palpable 
(prevention design). Initial dose and scheduling in pilot 
experiments ranged empirically. Employing this design, 
we found that as little as three doses of TTL-315 (40 mg/
kg) administered every other day one week after treatment 
began was sufficient to fully prevent outgrowth of MATB-
III tumors (Figure 3A). If tumors were allowed to grow 
to a bulky size (>2400 mm3) before drug administration, 
TTL-315 adminstered at the same dose slowed but did 
not block outgrowth (Figure 3B). However, in striking 
contrast, in bulky tumors where cisplatin chemotherapy 
was also limited in efficacy, co-administration of TTL-
315 at the same dose as before was sufficient to trigger 
dramatic regressions (Figure 3C). 
We sought to extend and confirm these observations 
in a different preclinical model of breast cancer, namely, 
the transgenic MMTV-neu mouse model of HER2-driven 
breast carcinoma. Multiparous female MMTV-Neu 
mice, maintained as previously described [15], present 
with a high incidence of autochthonous mammary gland 
carcinomas akin to the human experience in that different 
secondary ‘hits’, epigenetic pathways and immunoediting 
events are taken in different individual animals during 
Figure 2: TTL-315 exhibits glucose-dependent cytotoxic properties similar to HEDS. Equivalent numbers of cells from the 
cell population indicated were seeded in growth media and refed the following day with growth media that included or lacked glucose. 
Four hours later, TTL-315 or vehicle control was added at the concentrations indicated and cells were incubated for 24 hr before analysis 
as described in the Materials and Methods. The Y-axis presents the relative surviving fraction as a proportion of viable cells counted in 
replicate cultures (n = 3) at the time of TTL-315 or vehicle addition. Data was evaluated by Student’s T test. 
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Figure 3: TTL-315 blocks the growth of MATB-III mammary carcinoma and cooperates with cisplatin to trigger 
regression of bulky established tumors. Tumor volumes comparing control and experimental cohorts relative to the starting day 
of treatment is shown on the Y-axis in all panels. A. Prevention design. MATB-III tumor-bearing F344 rats with palpable tumors were 
administered 40 mg/kg TTL-315 or vehicle only (0.1 ml) by tail vein injection on the days indicated. Mean tumor volume at the start of 
treatment was 139±4 mm3 for mice in the control cohort (n = 5) and 127±12 mm3 for mice in the experimental cohort (n = 5). B. Treatment 
design. Rats with bulky tumors >2000 mm3 were treated as before on the days indicated. Mean tumor volume at the start of treatment was 
2837±204 mm3 for mice in the control cohort (n = 5) and 2848±538 mm3 for mice in the experimental cohort (n = 5). C. Cooperation with 
cisplatin. Rats with bulky tumors were subjected to the treatment design protocol as before except for the addition of cisplatin (2 mg/kg) 
which was administered at the times indicated to both cohorts. Mean tumor volume at the start of treatment was 2948±180 mm3 for mice 
in the control cohort (cisplatin only) (n=5) and was 2402±218 mm3 for mice in the experimental cohort (cisplatin + TTL-315) (n = 5). Data 
was evaluated by Student’s T test. 
Figure 4: TTL-315 blocks the growth of MMTV-neu mammary carcinoma and cooperates with cisplatin to promote 
regression of established tumors. Tumor volumes comparing control and experimental cohorts relative to the starting day of treatment 
is shown on a logarithmic scale on the Y-axis. Each dot represents a subject on trial (n). Horizontal bars in each dataset shows the mean of 
the data. Statistical significance was analyzed by ANOVA. MMTV-neu mice with spontaneously arising palpable mammary tumors (500-
1000 mm3) were recruited longitudinally to a trial in which TTL-315 (100 mg/kg), cisplatin (1 mg/kg) or vehicle only (0.1 ml volume) was 
administered by i.p. injection on days 1, 3, 5 of a two-week response trial. 
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tumor development. MMTV-neu mice were enrolled 
randomly into control and experimental treatment groups 
when tumors reached ~500-1000 mm3. Mice in different 
cohorts received vehicle only, TTL-315 (100 mg/kg), 
cisplatin (1 mg/kg) or both drugs on days 1,3,5 of a two-
week tumor response assay, a design described in detail 
in this model for other drug trials elsewhere [16-18]. Two 
weeks following initiation of the treatment, mice were 
euthanized for measurement of the final tumor sizes. A 
comparison of each subject in the cohorts relative to the 
starting day of treatment confirmed the antitumor activity 
of TTL-315 and its ability to leverage the efficacy of 
cisplatin in this model (Figure 4). In this model, TTL-315 
was quite potent with 3/10 subjects receiving this agent 
showed either no tumor growth or frank tumor regression. 
In combination with cisplatin, which produced no 
regressions by itself, TTL-315 elicited tumor regressions 
in 7/11 subjects. 
We further explored the antitumor properties 
of TTL-315 in the established Lewis lung carcinoma 
model (LLC1), where the potential for cooperation with 
radiotherapy was of interest based on studies of HEDS as 
a radiosensitizer [3-5, 19, 20]. In pilot trials, we obtained 
results from tests of TTL-315 (100 mg/kg) administered 
i.p. in the LLC1 lung tumor model that were similar to 
those reported above (Suppl. Figure 2A). LLC1 tumors 
did not respond to low doses of ionizing radiation tested 
(2 or 4 Gy), but at 8 Gy which slowed tumor growth 
the administration of TTL-315 on the same dose and 
schedule cooperated modestly to attenuate growth further 
(Suppl. Figure 2B). Overall, the results obtained in 
three established preclinical models of breast and lung 
carcinoma that are known for their aggressive properties 
supported the conclusion that TTL-315 could inhibit tumor 
growth, enhance the efficacy of DNA damaging therapies 
and trigger tumor regressions. 
TTL-315 activity does not rely on host 
immunocompetence or evident systemic toxicity
 Given emerging evidence of the importance 
of glucose metabolism on tumor immunity [21, 22], 
we asked whether the antitumor properties of TTL-
315 might be seated in immune alterations. For this 
direction, we employed B16 murine melanoma based 
on the importance of immune modulation in melanoma 
growth and therapeutic response. In this model system, 
i.p. administration of TTL-315 (40 mg/kg) on a similar 
schedule at 7, 10, and 13 days after palpable tumor-bearing 
mice were enrolled yielded tumor growth inhibitions in 
both immune-competent syngeneic C57BL6 hosts as well 
as in immune-incompetent nude mouse hosts (Figure 
5). While tumor growth differed subtly in each host, no 
significant differences in the growth inhibition elicted by 
TTL-315 were apparent. While combinations were not 
explored in this model, at a first level of investigation it did 
not appear as though TTL-315 relied upon T cell immunity 
for its in vivo activity, given the similar antitumor effects 
in these host animals. In a similar vein, we did not obtain 
evidence of systemic toxicity associated with TTL-315 
treatment as a conduit of its antitumor properties, based 
on observations from exploratory 7 and 28 day toxicity 
studies in mice (Suppl. Figure 3) and rats (data not shown) 
or comparisons of the weights of mice treated with TTL-
315 at doses of 40-100 mg/kg (single or multiple dosing). 
These data reinforced the conclusion that TTL-315 is 
safely tolerated in preclinical models without evidence of 
gross toxicity on its own or as bioreductively cleared to the 
monomeric form 2-mercaptopropionyl glycine (tiopronin). 
Figure 5: Antitumor properties of TTL-315 do not vary with host immunocompetency. C57BL6/J syngeneic hosts (BL6) or 
immunodeficient nude mice (nu/nu) were injected s.c. with 1 x 105 B16F10 cells (day 0) and enrolled randomly in control or experimental 
cohorts (n = 10 all cohorts). On days 7, 10, 13 mice were administered by i.p. injection vehicle only or 40 mg/kg TTL-315 (0.1 ml total 
volume). Tumor volumes based on calculations from caliper measurements were determined with an endpoint of 24 days in the experiment. 
Data was evaluated by Student’s T test.
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DISCUSSION
The results presented in this study offer an 
initial preclinical proof of concept for TTL-315 as an 
antimetabolite with potent antitumor activity. TTL-315 
is a disulfide, a thiol dimer, of the approved generic 
drug tiopronin (aka thiola) which has been used in 
clinic for many years to treat the disease cystinuria [23, 
24]. Bioreduction of TTL-315 yields two monomers of 
tiopronin, the pharmacology and toxicology for which 
has been well established clinically. Consistent with the 
results of preliminary exploratory toxicology conducted 
in rats and mice, the reduced form of TTL-315, tiopronin, 
is known to be safe. Therefore, one would expect the 
safety risks for TTL-315 development to be mitigated to 
a significant extent. Under normal conditions in healthy 
tissues, which are provided with sufficient nutrients, TTL-
315 is reduced relatively quickly to tiopronin. In contrast, 
accumulation of TTL-315 in the glucose-deprived 
microenvironment of a solid tumor, where it is not reduced 
quickly to tiopronin, would intensify competition for the 
precious glucose/OPPC/NADPH-dependent thiol-reducing 
activity which is critical to sustain cancer cell survival 
in the hostile tumor microenvironment. By stressing a 
system that is already strained in solid tumors, TTL-315 
impairs many local thiol redox-dependent functions, 
including DNA repair functions. Figure 6 presents a 
model which illustrates its tumor-selective antimetabolic 
effects, which are based on glucose insufficiency in solid 
tumor tissue. The strain imposed by TTL-315 in solid 
tumors is extended still further by the co-administration 
of DNA damaging therapies which tax the same thiol 
redox-dependent functions, suggesting a basis to 
explain the antitumor cooperativity that was observed in 
multiple preclinical models of cancer. In summary, our 
observations are consistent with the interpretation that 
TTL-315 attacks a metabolic weakness in solid tumors, 
one which is associated with limited safety risks based on 
the established safety and pharmacotoxicogical profile of 
its bioreductant monomer, tiopronin. 
NADPH is critically needed to sustain the relatively 
fragile state of thiol homeostasis in solid tumors. Thus, 
it is intriguing to consider whether this need may help 
explain the widespread activation of glycolysis in cancer 
cells, insofar as the OPPC pathway generating NADPH 
relies on glucose-6-phosphate synthesized as the first 
step in glycolysis. As noted above, hypoxic regions of 
tumors that are notoriously resistant to radiotherapy or 
chemotherapy are also glucose deprived [8]. Additionally, 
studies of tissue ischemia indicate that tissue damage 
occurs as much a result of glucose deprivation as hypoxia 
[25]. A connection between tissue ischemia, glucose 
deprivation, and cell death can be understood because 
under hypoxic conditions NADPH production through 
Figure 6: TTL-315 response model. TTL-315 is proposed to interfere with thiol redox homeostasis and elicit cell death in glucose-
deprived cells where its detoxification is inefficient. A detailed discussion of the bioreductive/detoxification pathways involved have been 
discussed elsewhere [10]. In the solid tumor microenvironment, the high glucose metabolism combined with a poor blood vasculature 
leads to glucose deprivation, low OPPC activity and reduced NADPH generation. This situation strains the levels of glutathione needed 
to preserve thiol homeostasis, which as a result becomes vulnerable to the additional stress created by dithiols that would be reduced by 
glutathione-dependent redox processes. By intensifying the competition for these processes, thiol redox control of critical cell proteins 
including DNA repair proteins is compromised. DNA-damaging chemotherapy and radiotherapy provide further strains that cooperate to 
heighten cellular demise. In attacking this weak point, TTL-315 as a dithiol stressor in glucose-deprived solid tumors may offer additional 
benefits to cancer management through production of its bioreductive product 2-mercaptopropionyl glycine (tiopronin), as discussed in the 
text.
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the glucose-dependent OPPC pathway is compromised 
to an extent that protein thiol homeostasis is threatened. 
The notion that the OPPC pathway is a point of metabolic 
vulnerability in solid tumors is supported by this study 
of TTL-315, and extended still further by more detailed 
cell biochemistry investigations of HEDS indicating that 
(i.) it is possible to selectively depress NADPH levels in 
glucose-deprived cancer cells, and (ii.) that this effect 
sensitizes cancer cells to cytotoxic chemotherapy by 
compromising thiol-dependent DNA repair proteins [3]. 
Under normal glucose conditions, TTL-315 is rapidly 
reduced to its monomeric form tiopronin, eliminating its 
cytotoxic bioactivity and deactivating its ability to attack 
a vulnerability only present in the inherently glucose-
deprived status of a solid tumor. 
As an oxidative cytotoxin, the relative specificity 
of TTL-315 for glucose-deprived cells seems unique in 
the literature. As noted elsewhere [10], most chemical 
oxidants exert their toxicity by general oxidation of lipids, 
proteins and DNA, lacking specificity for thiols and 
depleting non-protein thiols in the presence of glucose. 
Unlike other oxidants, TTL-315 was not expected to be 
especially toxic to protein or non-protein thiols [3, 4, 19]. 
Glutathione is the chief non-protein thiol in cells, helping 
maintain intracellular redox status by scavenging reactive 
oxygen species or serving as a substrate for enzymes that 
reduce oxidatively modified proteins, e.g. glutathionylated 
proteins [3, 19]. It is uncertain as yet the extent to which 
glutathione redox processes may be affected by TTL-315. 
However, under conditions of normal glucose levels, cells 
with normal OPPC activity reduce TTL-315 to tiopronin 
with little effect on protein and non-protein thiols, much 
like HEDS to ß-mercaptoethanol as discussed in detail 
elsewhere [10]. 
The production of tiopronin (2-mercaptopropionyl 
glycine) in normal tissues is an intriguing feature since 
it may yield additional benefits for cancer treatment. In 
human cancer cells, this compound exhibits collateral 
sensitization in relieving multidrug resistance (MDR) 
through a P-glycoprotein-independent mechanism where 
glutathione peroxidase has been implicated [26, 27]. 
Additionally, in a variety of preclinical model systems it 
has been reported to reduce emesis produced by widely 
used emetogenic chemotherapies like cisplatin [28-30]. 
Lastly, evidence has been presented in preclinical models 
that tiopronin can mitigate chemotherapy-induced liver 
and kidney toxicity [31-33], probably through antioxidant 
effects. Although these properties were not examined in 
the present work, their consideration as useful features of 
TTL-315 pharmacology offer a further impetus for future 
study of this unique compound. 
MATERIALS AND METHODS
Chemicals
TTL-315 was obtained by contract synthesis 
from Bio-101 and its structure was verified by mass 
spectroscopy. Stock solutions of each compound were 
prepared freshly as needed for dilution in cell culture or 
animal experiments in glucose-free DMEM. 
Cell culture
Rat intestinal epithelial (RIE) cell lines RIE/neo 
and RIE/Kras were generated and cultured as described 
previously [13] in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 5% fetal bovine serum 
(FBS) and antibiotics. RIE/neuT cells were generated 
by transformation with a mutant rat neu/Her-2 cDNA 
(neu-T) expression vector [34]. Cells were passaged 48 
hr after transfection in media containing 0.5 mg/ml G418 
and drug-resistant cells were pooled to confirm transgene 
expression by Western analysis along with anchorage-
independent growth capability (data not shown). Equal 
numbers of cells were seeded in multiwell dishes the 
day before replenishing with normal or glucose-deprived 
media. TTL-315 or control vehicle (DMSO) was added 
4 hr later and viable cell numbers were determined at 
times indicated by the HEDS-based assay CellCountEZ 
[14] (Rockland Immunochemicals). Glucose-deprived 
media was glucose-free DMEM containing 5% 
FBS and antibiotics. 13762 MATB-III rat mammary 
adenocarcinoma cells (ATCC) were cultured in McCoy’s 
5A modified medium supplemented with 10% FBS and 
antibiotics. LLC-1 murine Lewis lung carcinoma cells 
(ATCC) and B16F10 murine melanoma cells (ATCC) 
were cultured in DMEM supplemented with 10% FBS 
and antibiotics. 
Tumor models and treatments
Established preclinical models of cancer employed 
in this study included the Fischer rat mammary 
adenocarcinoma MATB-III, murine Lewis lung carcinoma 
(LLC-1), murine melanoma B16F10 (B16) and murine 
MMTV-neu mammary carcinoma. All studies were 
reviewed and approved by the Institutional Animal Care 
and Use Committee of the Lankenau Institute for Medical 
Research and were conducted in a vivarium accredited 
by the American Association for the Accreditation of 
Laboratory Animal Care (AAALAC). MATB-III tumors 
were initiated by orthotopic injection of Fischer 344 
rats (Charles River) with 1 x 105 cells suspended in PBS 
into a mammary fat pad. LLC-1 or B16 tumors were 
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initiated by subcutaneous injection of C57BL6/J mice 
(Jackson Laboratory) of 1x106 or 1x105 cells suspended in 
PBS, respectively. The transgenic mouse strain FVB/N-
Tg(MMTVneu)202Mul/J abbreviated here as MMTV-neu 
(Jackson Laboratory) harbors homozygous copies of a 
rat c-Neu transgene controlled by the mouse mammary 
tumor virus promoter [35] MMTV-neu mice maintained 
by in-house husbandry were employed as described in 
detail elsewhere [16, 36]. Tumor size was determined by 
caliper measurements. Tumor volumes in the B16 and 
MMTV-neu models were calculated based on the formula 
for determining a prolapsed elliptoid (d2_l/0.52) where 
d is the shorter of the two orthogonal measurements. 
Tumor volumes in the MATB-III and LLC-1 models 
were calculated based on caliper measurements in three 
mutually perpendicular diameters (A,B,C) volume 
determined as V = (p/6)xAxBxC. For TTL-315 treatments 
as indicated, tumor-bearing mice with similarly sized 
tumors were randomized into control and experimental 
groups before administration of compounds prepared in 
cell growth media via tail vein injection (MATB-III) or 
intraperitoneal injection (LLC-1, B16, MMTV-neu). 
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